Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (3786)	9/20/1999 11:02:00 AM
From: DanZ	Read Replies (2) \| Respond to of 10293

I don't care what you think of me. I back my opinions up with facts, unlike most of you here. Along those lines, it took me all of 5 minutes to find an article that refutes your comments below. "The FDA's statisticians, on the other hand, would probably bust a gut laughing if a drug company were to submit such a small clinical trial as proof of a drugs efficacy." "If you did, you would not assume that a test population of 200 patients is clinically significant given the fact that millions of people suffer from colds each year and that these colds can potentially be caused by 200 different viral types." Source: acponline.org Annals of Internal Medicine Zinc Gluconate Lozenges for Treating the Common Cold. A Randomized, Double-Blind, Placebo-Controlled Study Annals of Internal Medicine, 15 July 1996. 125:81-88. Sherif B. Mossad, MD; Michael L. Macknin, MD; Sharon V. Medendorp, MPH; and Pamela Mason, BSN, MBA Objective: To test the efficacy of zinc gluconate lozenges in reducing the duration of symptoms caused by the common cold. Patients: 100 employees of the Cleveland Clinic who developed symptoms of the common cold within 24 hours before enrollment.